Order of the Supreme Court of India in the matter of Network of People Living With HIV/AIDS & Others Vs Union of India & Others dated 24/02/2025. The Supreme Court (SC), February 24, 2025 has directed all states to file their affidavits addressing concerns raised about antiretroviral therapy (ART) drugs …
Blockbuster anti-cancer drug Glivec costs $7,367 for a month’s dosage Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multibillion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs’ claims of cheap access and affordability for …
Drug maker Lupin Ltd is expected to soon launch its generic version of the anti-HIV drug, Combivir, in the United States. The move was likely to lend a significant upside to the Mumbai-based company’s bottom line in the forthcoming quarters, a source said. Lupin’s drug, a combination of lamividine and …
Several drug manufacturers accused of colluding with the sector regulator and medical experts to allegedly violate approval norms have denied the charges, claiming that the local authority acted independently. The Parliamentary Standing Committee on Health and Family Welfare had on Tuesday released a scathing report, alleging “apparent nexus between the …
Under attack over the functioning of the Central Drugs Standard Control Organisation (CDSCO), the Ministry of Health and Family Welfare today claimed to have “already taken several steps” to plug the loopholes in the system. Reacting to a standing committee report on the functioning of CDSCO, tabled in Parliament yesterday, …
Nexus To Get Approvals: MPs’ Panel New Delhi: Some drug companies seem to have been writing scientific recommendations of their own products and submitting them to the Drug Controller General of India after getting them endorsed by top doctors, according to a report by the parliamentary standing committee on health …
‘Purpose Not Being Served As Towns Aren’t Ethnically Diverse’ New Delhi: Smaller cities seem to have become prime target for drug trials. While pharma companies have claimed over the last few years that most of their drug trials were taking place in “cosmopolitan towns” which have a heterogeneous population, comprising …
Drugs which developed countries have banned or withdrawn from markets over safety concerns are in open and brazen circulation in India. In a damning indictment of the Health Ministry and Drug Controller General of India for compromising safety of Indians by disregarding regulatory procedures in respect of new drugs discovered …
In a scrutiny of 39 randomly picked drugs in India, a parliamentary panel found that in case of 11 drugs (28%), mandatory phase-III clinical trials were not conducted. Is the pill you're popping safe? Well, one cannot be certain. Several highly popular medicines in India are being sold without having …
NEW DELHI: Officials in Central Drugs Standard Control Organization (CDSCO) seem to have "colluded with private interests" to get the controversial drug Letrozole approved in India "in a clear violation of laws" for use against infertility. Now, the parliamentary standing committee on health and family welfare has asked the Union …
Till now, doctors in the private sector were free to treat TB patients, and weren't required to keep a record. India has finally declared tuberculosis (TB) a notifiable disease. The announcement signifies that with immediate effect, all private doctors, caregivers and clinics treating a patient suffering from TB will have …
German pharmaceutical company Bayer AG has formally lodged a challenge against a landmark Indian ruling that allowed a domestic generic drug-maker to produce a low-cost version of an anti-cancer drug for the Indian market. The appeal was filed on Friday 4 May with India's Intellectual Property Appellate Board.
The government has recently stopped giving permission to foreign companies and overseas investors to buy into Indian drugmakers till clear guidelines regarding foreign direct investment in the sector are finalised. The Foreign Investment Promotion Board (FIPB), the nodal agency that approves investments in India, deferred four proposals at its March …
Liberalisation measures in the pharmaceutical sector have brought about major changes in the industrial licensing policy, import restrictions, foreign direct investment and production controls. It was feared that firms would shift from indigenous production to imports, especially of bulk drugs, and this concern was aggravated with the change in the …
In June 2008, when Japanese drugmaker Daiichi Sankyo acquired Ranbaxy Laboratories, Daiichi’s chief executive Takashi Shoda said, “Acquisitions are more attractive than alliances,” setting the stage for more Indian companies to be taken over by their powerful European and American counterparts. But, today, Big Pharma thinks otherwise. With Indian drug …
The Delhi Drug Policy for National Capital Territory (NCT) was constituted in 1994. For its effective implementation a step by step approach was adopted. To start with an essential drug list (EDL) was formulated which has since been revised every two years. As part of the implementation of the Delhi …
The scale up of DOTS in India is one of the greatest public health accomplishments, and yet undiagnosed and poorly managed TB continues to fuel the epidemic such that India continues to have the highest number of TB cases in the world. Recognizing these challenges, the Government of India has …
The Phase II (2006-2012) of the Revised National Tuberculosis Control Programme (RNTCP) has been successful in achieving its objectives. Tuberculosis (TB) disease burden (prevalence and mortality) in India has reduced significantly when compared to 1990 levels, and India is on track to achieve the TB related millennium development goals. Despite …
Pharma cos worried that the dept is moving away from its stance on pricing of essential drugs. The Department of Pharmaceuticals has told a group of ministers that competition does not necessarily lead to reduction in medicine prices, raising concern among the industry that the department is moving away from …
Bhubaneswar: Health and family welfare minister Prasanna Acharya on Saturday said that the state government has decided to strengthen the infrastructure of the drugs control administration to ensure availability of quality drugs to the patients. Addressing a two-day conference of Drug Inspectors here, Acharya said as part of upgradation of …
India on Wednesday launched its first indigenously manufactured anti-malaria new-age drug Synriam. The drug, produced by Ranbaxy Laboratories, was formally introduced for marketing here. The drug, launched by Health Minister Ghulam Nabi Azad in the presence of Science and Technology Minister Vilasrao Deshmukh, has been developed by the company in …
